These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8451009)

  • 1. Aspartame use in Parkinson's disease.
    Karstaedt PJ; Pincus JH
    Neurology; 1993 Mar; 43(3 Pt 1):611-3. PubMed ID: 8451009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartame and sucrose produce a similar increase in the plasma phenylalanine to large neutral amino acid ratio in healthy subjects.
    Burns TS; Stargel WW; Tschanz C; Kotsonis FN; Hurwitz A
    Pharmacology; 1991; 43(4):210-9. PubMed ID: 1771173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aspartame on plasma amino acid profiles of diabetic patients with chronic renal failure.
    Gupta V; Cochran C; Parker TF; Long DL; Ashby J; Gorman MA; Liepa GU
    Am J Clin Nutr; 1989 Jun; 49(6):1302-6. PubMed ID: 2729170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.
    Pincus JH; Barry KM
    Arch Neurol; 1987 Oct; 44(10):1006-9. PubMed ID: 3632370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible neurologic effects of aspartame, a widely used food additive.
    Maher TJ; Wurtman RJ
    Environ Health Perspect; 1987 Nov; 75():53-7. PubMed ID: 3319565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.
    Eriksson T; Magnusson T; Carlsson A; Linde A; Granérus AK
    J Neural Transm; 1984; 59(3):229-40. PubMed ID: 6429277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution.
    Burns TS; Stargel WW; Hurwitz A
    Metabolism; 1990 Nov; 39(11):1200-3. PubMed ID: 2233283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.
    Nutt JG; Woodward WR; Carter JH; Trotman TL
    J Neurol Neurosurg Psychiatry; 1989 Apr; 52(4):481-7. PubMed ID: 2738591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartame, behavior, and cognitive function in children with attention deficit disorder.
    Shaywitz BA; Sullivan CM; Anderson GM; Gillespie SM; Sullivan B; Shaywitz SE
    Pediatrics; 1994 Jan; 93(1):70-5. PubMed ID: 7505423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated ingestion of aspartame-sweetened beverages: further observations in individuals heterozygous for phenylketonuria.
    Stegink LD; Filer LJ; Bell EF; Ziegler EE; Tephly TR; Krause WL
    Metabolism; 1990 Oct; 39(10):1076-81. PubMed ID: 2215254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A balanced carbohydrate: protein diet in the management of Parkinson's disease.
    Berry EM; Growdon JH; Wurtman JJ; Caballero B; Wurtman RJ
    Neurology; 1991 Aug; 41(8):1295-7. PubMed ID: 1866021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspartame: review of recent experimental and observational data.
    Janssen PJ; van der Heijden CA
    Toxicology; 1988 Jun; 50(1):1-26. PubMed ID: 3291200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aspartame and protein, administered in phenylalanine-equivalent doses, on plasma neutral amino acids, aspartate, insulin and glucose in man.
    Møller SE
    Pharmacol Toxicol; 1991 May; 68(5):408-12. PubMed ID: 1946186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartame: neuropsychologic and neurophysiologic evaluation of acute and chronic effects.
    Spiers PA; Sabounjian L; Reiner A; Myers DK; Wurtman J; Schomer DL
    Am J Clin Nutr; 1998 Sep; 68(3):531-7. PubMed ID: 9734727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of aspartame in non-insulin-dependent diabetics.
    Stern SB; Bleicher SJ; Flores A; Gombos G; Recitas D; Shu J
    J Toxicol Environ Health; 1976 Nov; 2(2):429-39. PubMed ID: 1011296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The debate over neurotransmitter interaction in aspartame usage.
    Choudhary AK; Lee YY
    J Clin Neurosci; 2018 Oct; 56():7-15. PubMed ID: 30318075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aspartame-derived phenylalanine on neutral amino acid uptake in human brain: a positron emission tomography study.
    Koeppe RA; Shulkin BL; Rosenspire KC; Shaw LA; Betz AL; Mangner T; Price JC; Agranoff BW
    J Neurochem; 1991 May; 56(5):1526-35. PubMed ID: 2013754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame.
    Hjelle JJ; Dudley RE; Marietta MP; Sanders PG; Dickie BC; Brisson J; Kotsonis FN
    Pharmacology; 1992; 44(1):48-60. PubMed ID: 1553388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated ingestion of aspartame-sweetened beverage: effect on plasma amino acid concentrations in individuals heterozygous for phenylketonuria.
    Stegink LD; Filer LJ; Baker GL; Bell EF; Ziegler EE; Brummel MC; Krause WL
    Metabolism; 1989 Jan; 38(1):78-84. PubMed ID: 2909831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.